Dechert Advises Resolve BioSciences in Its US$71 Million Series B Financing Round

 
November 10, 2022

Dechert LLP advised Resolve BioSciences GmbH, the pioneer in Molecular Cartography™ technology, on its US$71 million Series B financing round. Resolve is based in Monheim am Rhein, Germany.

The Series B financing round was led by Patient Square Capital, a health care investment firm, and included participation from EDBI, PS Capital, Alafi Capital and NRW.BANK.

Dechert was also responsible for advising Resolve Biosciences in its previous US$24 million Series A financing round. Following this latest round of funding, the company has now raised over US$100 million.

Resolve’s Molecular Cartography platform is a groundbreaking multi-analyte and highly multiplex spatial analysis technology. This technology provides the highest-resolution view of subcellular, single-molecule biology, allowing scientists around the world to gain new insights related to COVID-19 pathology as well as neurology, oncology, and developmental biology.

The Dechert team advising Resolve Biosciences included Munich-based private equity partners Giovanni Russo, Federico G. Pappalardo and Carina Klaes-Staudt, counsel Christian Böhme and associate Florian Leitsbach.

To find out more about Dechert’s private equity practice, click here.

About Dechert

Dechert is a leading global law firm with 22 offices around the world. The firm advises on matters and transactions of the greatest complexity, bringing energy, creativity, and efficient management of legal issues to deliver commercial and practical advice for clients.

Subscribe to Dechert Updates